Glaukos (GKOS) Stock Price, News & Analysis

Company Overview

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of novel therapies for glaucoma and other chronic eye diseases. Founded in 1998 as NexGen Ophthalmics and rebranded in 2015, the company is headquartered in San Clemente, California. Glaukos is best known for pioneering micro-invasive glaucoma surgery (MIGS) devices that aim to reduce intraocular pressure with less tissue disruption than traditional glaucoma surgeries.

The company’s flagship products include the iStent family of implants—small, porous titanium micro-stents designed to be placed in the eye’s drainage system during cataract surgery to improve fluid outflow. Successive generations, such as the iStent inject and iStent infinite, offer multiple stents for greater anatomical coverage. Beyond MIGS, Glaukos markets the iDose TR intracameral implant that delivers sustained release of intraocular pressure-lowering medication, as well as the Avedro platform for corneal cross-linking to treat keratoconus and other corneal ectatic disorders.

Glaukos operates through a combination of direct sales forces and distribution partners, serving surgeons and patients across the United States, Europe, Asia-Pacific and Latin America. The company holds regulatory approvals in major markets, including FDA clearance in the U.S., CE marking in Europe and PMDA approval in Japan. Manufacturing facilities span North America and Latin America, supporting both product supply and ongoing research and development initiatives.

The leadership team at Glaukos brings together experienced executives in regulatory affairs, clinical research and global commercialization. Guided by a board that includes leading ophthalmologists and life-science professionals, the company continues to expand its product pipeline in glaucoma, corneal and retinal spaces while pursuing strategic collaborations to enhance its capabilities in drug delivery and surgical innovation.

Key Stats

• Today's Range: $100.92 to $103.06
• 50-Day Range: $83.21 to $103.42
• 52-Week Range: $77.10 to $163.71
• Volume: 512,308 shs
• Average Volume: 738,034 shs
• Market Capitalization: $5.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $134.67
• Consensus Rating: Moderate Buy

Glaukos Stock Analysis - MarketRank™

Glaukos scored higher than 89% of companies evaluated by MarketBeat, and ranked 127th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Glaukos has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Glaukos is -43.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Glaukos is -43.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Glaukos has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.39% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Glaukos has recently increased by 3.38%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Glaukos does not currently pay a dividend.

Dividend Growth

Glaukos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

7.39% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Glaukos has recently increased by 3.38%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

Glaukos has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Glaukos this week, compared to 7 articles on an average week.

Search Interest

Only 4 people have searched for GKOS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Glaukos to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Glaukos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Glaukos is held by insiders.

Percentage Held by Institutions

99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GKOS Stock Analysis - Frequently Asked Questions

How have GKOS shares performed this year?

Glaukos' stock was trading at $149.94 on January 1st, 2025. Since then, GKOS shares have decreased by 31.5% and is now trading at $102.65.
View the best growth stocks for 2025 here.

How were Glaukos' earnings last quarter?

Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings results on Wednesday, April, 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos's revenue for the quarter was up 24.6% compared to the same quarter last year.
Read the conference call transcript.

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:GKOS
• CIK: 1192448
• Web: www.glaukos.com
• Phone: (949) 367-9600
• Fax: 949-367-9984
• Employees: 780
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $134.67
• High Stock Price Target: $182.00
• Low Stock Price Target: $72.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.37 million
• Net Margins: -31.40%
• Pretax Margin: -30.40%
• Return on Equity: -10.66%
• Return on Assets: -8.06%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 6.49
• Quick Ratio: 5.62

Sales & Book Value

• Annual Sales: $383.48 million
• Price / Sales: 15.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.91 per share
• Price / Book: 7.38

Miscellaneous

• Outstanding Shares: 57,140,000
• Free Float: 53,484,000
• Market Cap: $5.87 billion
• Optionable: Optionable
• Beta: 0.82